Abstract

Thyroid hormone (TH) and thyroid hormone receptor (THR) regulate stem cell proliferation and differentiation during development, as well as during tissue renewal and repair in the adult. THR undergoes posttranslational modification by small ubiquitin-like modifier (SUMO). We generated the THRA (K283Q/K288R)−/− mouse model for in vivo studies and used human primary preadipocytes expressing the THRA sumoylation mutant (K283R/K288R) and isolated preadipocytes from mutant mice for in vitro studies. THRA mutant mice had reduced white adipose stores and reduced adipocyte cell diameter on a chow diet, compared to wild-type, and these differences were further enhanced after a high fat diet. Reduced preadipocyte proliferation in mutant mice, compared to wt, was shown after in vivo labeling of preadipocytes with EdU and in preadipocytes isolated from mice fat stores and studied in vitro. Mice with the desumoylated THRA had disruptions in cell cycle G1/S transition and this was associated with a reduction in the availability of cyclin D2 and cyclin-dependent kinase 2. The genes coding for cyclin D1, cyclin D2, cyclin-dependent kinase 2 and Culin3 are stimulated by cAMP Response Element Binding Protein (CREB) and contain CREB Response Elements (CREs) in their regulatory regions. We demonstrate, by Chromatin Immunoprecipitation (ChIP) assay, that in mice with the THRA K283Q/K288R mutant there was reduced CREB binding to the CRE. Mice with a THRA sumoylation mutant had reduced fat stores on chow and high fat diets and reduced adipocyte diameter.

Details

Title
Thyroid hormone receptor alpha sumoylation modulates white adipose tissue stores
Author
Liu, Yan-Yun 1 ; Jiang, Jingjing 2 ; Ke, Sujie 3 ; Milanesi, Anna 1 ; Abe, Kiyomi 4 ; Gastelum, Gilberto 1 ; Li, Jianrong 3 ; Brent, Gregory A. 1 

 David Geffen School of Medicine at UCLA, and Veterans Affairs Greater Los Angeles Healthcare System, Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Physiology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718) 
 David Geffen School of Medicine at UCLA, and Veterans Affairs Greater Los Angeles Healthcare System, Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Physiology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); Zhongshan Hospital, Fudan University, Department of Endocrinology, Shanghai, China (GRID:grid.413087.9) (ISNI:0000 0004 1755 3939) 
 David Geffen School of Medicine at UCLA, and Veterans Affairs Greater Los Angeles Healthcare System, Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Physiology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); Union Hospital, Fujian Medical University, Department of Endocrinology, Fuzhou, China (GRID:grid.411176.4) (ISNI:0000 0004 1758 0478) 
 David Geffen School of Medicine at UCLA, and Veterans Affairs Greater Los Angeles Healthcare System, Division of Endocrinology, Diabetes and Metabolism, Departments of Medicine and Physiology, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); Keio University School of Medicine, Department of Pediatrics, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959); Saiseikai Central Hospital, Tokyo, Japan (GRID:grid.270560.6) (ISNI:0000 0000 9225 8957) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2610660212
Copyright
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.